Acetylenic linkers in lead compounds: A study of the stability of the propargyl-linked antifolates

Drug Metabolism and Disposition

Volumn 40, Issue 10, 2012, Pages 2002-2008

  Zhou, Wangda ^a   Viswanathan, Kishore ^a   Hill, Dennis ^a   Anderson, Amy C ^a   Wright, Dennis L ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLENE; ALKYNE; DIHYDROFOLATE REDUCTASE; DRUG METABOLITE; FOLIC ACID ANTAGONIST; WATER;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG STABILITY; DRUG STRUCTURE; ENZYME INHIBITION; HALF LIFE TIME; HYDROPHOBICITY; IC 50; IN VITRO STUDY; INTESTINE FLUID; LIVER MICROSOME; METABOLITE; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR WEIGHT; MOUSE; NONHUMAN; OXIDATION KINETICS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; STOMACH JUICE;

ALKYNES; ANIMALS; BIOTRANSFORMATION; DRUG DESIGN; DRUG STABILITY; FOLIC ACID ANTAGONISTS; HALF-LIFE; KINETICS; MICE; MICROSOMES, LIVER; MODELS, MOLECULAR; MOLECULAR STRUCTURE; OXIDATION-REDUCTION; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDROFOLATE DEHYDROGENASE;

FUNGI;

EID: 84866459005     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.046870     Document Type: Article

References (19)

1. Beierlein JM, Frey KM, Bolstad DB, Pelphrey PM, Joska TM, Smith AE, Priestley ND, Wright DL, and Anderson AC (2008) Synthetic and crystallographic studies of a new inhibitor series targeting Bacillus anthracis dihydrofolate reductase. J Med Chem 51:7532-7540.
2. Bolstad DB, Bolstad ES, Frey KM, Wright DL, and Anderson AC (2008) Structure-based approach to the development of potent and selective inhibitors of dihydrofolate reductase from Cryptosporidium. J Med Chem 51:6839-6852.
3. Frey KM, Georgiev I, Donald BR, and Anderson AC (2010a) Predicting resistance mutations using protein design algorithms. Proc Natl Acad Sci U S A 107:13707-13712.
4. Frey KM, Liu J, Lombardo MN, Bolstad DB, Wright DL, and Anderson AC (2009) Crystal structures of wild-type and mutant methicillin-resistant Staphylococcus aureus dihydrofolate reductase reveal an alternate conformation of NADPH that may be linked to trimethoprim resistance. J Mol Biol 387:1298-1308.
5. Frey KM, Lombardo MN, Wright DL, and Anderson AC (2010b) Towards the understanding of resistance mechanisms in clinically isolated trimethoprim-resistant, methicillin-resistant Staphylococcus aureus dihydrofolate reductase. J Struct Biol 170:93-97.
6. Hill DW, Kertesz TM, Fontaine D, Friedman R, and Grant DF (2008) Mass spectral metabonomics beyond elemental formula: chemical database querying by matching experimental with computational fragmentation spectra. Anal Chem 80:5574-5582.
7. Huang WS, Metcalf CA, Sundaramoorthi R, Wang Y, Zou D, Thomas RM, Zhu X, Cai L, Wen D, Liu S, et al. (2010) Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3- yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl) phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. J Med Chem 53:4701-4719.
8. Kerns EH and Di L (2008) Drug-like Properties: Concepts, Structure, Design and Methods, Academic Press, Burlington.
9. King AO and Yasuda N (2004) Palladium-catalyzed cross-coupling reactions in the synthesis of pharmaceuticals, in Topics Organometallic Chemistry vol 6, pp 205-245, Springer-Verlag, Heidelberg.
10. Lindberg J, Sigurdsson S, Löwgren S, Andersson HO, Sahlberg C, Noréen R, Fridborg K, Zhang H, and Unge T (2002) Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant. Eur J Biochem 269:1670-1677. (Pubitemid 34304466)
11. Liu J, Bolstad DB, Smith AE, Priestley ND, Wright DL, and Anderson AC (2008) Structureguided development of efficacious antifungal agents targeting Candida glabrata dihydrofolate reductase. Chem Biol 15:990-996.
12. Liu J, Bolstad DB, Smith AE, Priestley ND, Wright DL, and Anderson AC (2009) Probing the active site of Candida glabrata dihydrofolate reductase with high resolution crystal structures and the synthesis of new inhibitors. Chem Biol Drug Des 73:62-74.
13. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, et al. (2009) AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16:401-412.
14. Paulsen JL, Bendel SD, and Anderson AC (2011) Crystal structures of Candida albicans dihydrofolate reductase bound to propargyl-linked antifolates reveal the flexibility of active site loop residues critical for ligand potency and selectivity. Chem Biol Drug Des 78:505-512.
15. Paulsen JL, Liu J, Bolstad DB, Smith AE, Priestley ND, Wright DL, and Anderson AC (2009) In vitro biological activity and structural analysis of 2,4-diamino-5-(2′-arylpropargyl)pyrimidine inhibitors of Candida albicans. Bioorg Med Chem 17:4866-4872.
16. Pelphrey PM, Popov VM, Joska TM, Beierlein JM, Bolstad ES, Fillingham YA, Wright DL, and Anderson AC (2007) Highly efficient ligands for dihydrofolate reductase from Cryptosporidium hominis and Toxoplasma gondii inspired by structural analysis. J Med Chem 50:940-950. (Pubitemid 46393997)
17. Ramanathan R (2011) Mass Spectrometry in Drug Metabolism and Pharmacokinetics, John Wiley & Sons, Hoboken.
18. Sigel CW, Grace ME, and Nichol CA (1973) Metabolism of trimethoprim in man and measurement of a new metabolite: a new fluorescence assay. J Infect Dis 128:S580-S583.
19. Viswanathan K, Frey KM, Scocchera EW, Martin BD, Swain PW, Alverson JB, Priestley ND, Anderson AC, and Wright DL (2012) Toward new therapeutics for skin and soft tissue infections: propargyl-linked antifolates are potent inhibitors of MRSA and Streptococcus pyogenes. PLoS ONE 7:e29434.